

Applicant(s) : Roberto BURIONI
U.S. Serial No. : 10/502,307
Filed : July 22, 2004
Page : 3

Amendments To The Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 - 29. Canceled

30. (New) A composition for treating HCV infection or preventing viral transmission in a subject comprising administering an effective amount of isolated antibody or its functional fragment, comprising of the following sequences of variable parts of the heavy chain, e 137 Heavy chain (HC):
LLEQSGSEVKVPGSSSLKVSCKTSGGTFSTYTFSWVRQAPGQGLEWMGGITPIIGIANIYARNF
QDRVITADESTSTVYMEVRLRSEDNAVYYCAKTSEVTATRGRTFFYSAMDVWGQGT
[SEQ ID No. 7]

and of the light chain, e 137 Light chain (LC):

MAELTQSPSFLSASVGDRVITICRASQGISNYLAWYQQKPGKAPKLLIYAASLTQSGVPSRF
SGSGSWTEFTLTISRLQPEDFATYYCQHLNTPPWTFGQGT. [SEQ ID No. 8]

31. (New) The composition of claim 30, wherein the said antibody or its fragment is the human monoclonal antibody Fab fragment e137 or a full-size human monoclonal antibody containing said Fab fragment.

32. (New) A composition for treating HCV infection or preventing viral transmission in a subject comprising administering an effective amount of isolated antibody or its functional fragment, comprising of the following sequences of variable parts of the heavy chain, e 301 Heavy chain (HC):
LLEQSGSEVKKPGSSVRVSCTTSGGTLSDYGFNWLQAPGQGPWGGIIPFRRTTYGQKF
QGRLTITADESTGATYMELESSLRSDDTAVYYCAREKVSVLTTGGKSLHYFEYWGKGT [SEQ ID No. 9]

and of the light chain, e 301 Light chain (LC):

MAELTQSPATLSVSPGERATLSCRASQSVSSRLAWYQQKRGQAPSLLIYDTSSRATGVPARF
SASGSGTQFTLTIISSLQSEDFALYYCQQYNDWPFSTFGQGT. [SEQ ID No. 10]

Applicant(s) : Roberto BURIONI
U.S. Serial No. : 10/502,307
Filed : July 22, 2004
Page : 4

33. (New) The composition of claim 32, wherein the said antibody or its fragment is the human monoclonal antibody Fab fragment e301 or a full-size human monoclonal antibody containing said Fab fragment.

34. (New) The composition of claim 30 wherein the human antibody is a full-size IgG1 molecule.

35. (New) The composition of claim 31 wherein the human antibody is a full-size IgG1 molecule.

36. (New) The composition of claim 32 wherein the human antibody is a full-size IgG1 molecule.

37. (New) The composition of claim 33 wherein the human antibody is a full-size IgG1 molecule.

38. (New) Composition for anti-HCV therapy comprising in a therapeutically effective amount at least a human antibody, or its functional fragments, said antibody or its fragment being the human monoclonal antibody Fab fragments e301 or e137, or a full-size human monoclonal antibody containing any of said Fab fragments.

39. (New) The composition according to claim 38 for parenteral or topical use in gel, crème, ointment and ovule formulations.